EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)

Randomized Study on Different Radiation Doses in Neoadjuvant Chemoradiation Therapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma (Neo-DRATEC Trial)

Yang Yang, Youhua Jiang, Changchun Wang, Jianqing Li, Xia Zhou, Wu'an Bao, Mengyuan Chen, Kaiyi Tao, Jie Wu, Shi Wang, Rongwei Ruan, Yali Tao und 6 weitere

International Journal of Radiation Oncology*Biology*Physics · 2026

DOI: 10.1016/j.ijrobp.2026.02.205 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026. Verfasst von Yang Yang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Radiotherapy, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Neoadjuvant Therapy, Esophageal Squamous Cell Carcinoma, Chemoradiotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Medical Science and Technology Project of Zhejiang Province, Natural Science Foundation of Zhejiang Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Radiation dose selection for neoadjuvant chemoradiation therapy (nCRT) in esophageal squamous cell carcinoma (ESCC) varies widely in clinical practice, and prospective randomized data addressing this question are lacking. This trial compared 2 commonly used radiation dose regimens in nCRT for resectable thoracic ESCC. METHODS AND MATERIALS: This single-center, phase 2 prospective, randomized controlled trial enrolled patients with locally advanced thoracic ESCC from February 22, 2018, to February 22, 2021. Patients were randomized 1:1 to receive nCRT with either 50.4 Gy/28F or 41.4 Gy/23F, concurrent with weekly paclitaxel and carboplatin. The primary endpoint was 2-year progression-free survival (PFS). RESULTS: A total of 147 patients were randomized (50.4 Gy, n = 72; 41.4 Gy, n = 75), of whom 101 underwent surgical resection. Pathologic complete response occurred in 23 of 46 patients (50.0%) in the 50.4-Gy group and 18 of 55 patients (32.7%) in the 41.4-Gy group (P = .078). Using major pathologic response (MPR) as an alternative endpoint, the 50.4 Gy/28F regimen significantly increased the MPR rate to 73.9%, compared with 52.7% in the low-dose group (P = .029). In the intention-to-treat population analysis, the 2-year PFS rates were 56.7% for the high-dose group and 49.3% for the low-dose group, with a hazard ratio (HR) of 0.72 (95% CI, 0.46-1.11; P = .14). Two-year overall survival (OS) rates were similar between groups. Grade ≥2 radiation esophagitis occurred more frequently in the 50.4-Gy group, whereas postoperative complication rates were comparable. CONCLUSIONS: Dose escalation from 41.4 to 50.4 Gy in nCRT for resectable ESCC did not improve PFS or OS but was associated with a higher MPR rate and increased esophagitis. These findings support current evidence that routine dose escalation does not confer a survival advantage, while providing randomized ESCC-specific data to inform individualized treatment decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal NeoplasmsNeoadjuvant TherapyEsophageal Squamous Cell CarcinomaChemoradiotherapyHumansRadiotherapy DosagePaclitaxelFemaleMiddle AgedProspective StudiesMaleCarboplatinAgedPathologic Complete ResponseProgression-Free SurvivalEsophagitisAdultAntineoplastic Combined Chemotherapy Protocols

Substanzen

PaclitaxelCarboplatin

Autor:innen und Institutionen

  • Department of Thoracic Radiotherapy, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
  • Department of Esophageal Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
  • Endoscopy Center, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
  • Department of Radiology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
  • Department of Clinical Study, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
  • Department of Pathology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.

Förderung

  • Medical Science and Technology Project of Zhejiang Province
  • Natural Science Foundation of Zhejiang Province

Zitieren

APA

Yang, Y., Jiang, Y., Wang, C., Li, J., Zhou, X., Bao, W., Chen, M., Tao, K., Wu, J., Wang, S., Ruan, R., Tao, Y., Song, G., Li, R., Wang, L., Su, D., Qiu, G., & Chen, Q. (2026). Randomized Study on Different Radiation Doses in Neoadjuvant Chemoradiation Therapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma (Neo-DRATEC Trial). International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2026.02.205

Vancouver

Yang Y, Jiang Y, Wang C, Li J, Zhou X, Bao W, et al. Randomized Study on Different Radiation Doses in Neoadjuvant Chemoradiation Therapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma (Neo-DRATEC Trial). International Journal of Radiation Oncology*Biology*Physics. 2026. doi:10.1016/j.ijrobp.2026.02.205

BibTeX
@article{Yang2026,
  author = {Yang, Yang and Jiang, Youhua and Wang, Changchun and Li, Jianqing and Zhou, Xia and Bao, Wu'an and Chen, Mengyuan and Tao, Kaiyi and Wu, Jie and Wang, Shi and Ruan, Rongwei and Tao, Yali and Song, Ge and Li, Runhua and Wang, Le and Su, Dan and Qiu, Guoqin and Chen, Qixun},
  title = {Randomized Study on Different Radiation Doses in Neoadjuvant Chemoradiation Therapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma (Neo-DRATEC Trial)},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2026},
  doi = {10.1016/j.ijrobp.2026.02.205}
}
Kostenlos starten →